Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA

FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023 ... | March 8, 2022

Related Keywords

New York ,United States ,Russia ,Ukraine ,Amsterdam ,Noord Holland ,Netherlands ,Onno Holleboom ,Pascaline Clerc ,Aude Lepreux ,Eli Lilly ,Pierre Broqua ,Patricial Bank ,Brunswick Group ,Exchange Commission On ,Amsterdam University Medical Centers ,Boehringer Ingelheim ,Drug Administration ,Nasdaq ,Global External Affairs ,Long Island City ,Euronext Paris ,Chief Scientist Officer ,Investigational New Drug ,Principal Investigator ,Nasdaq Global Market ,Global External ,Roquet Montegon ,Private Securities Litigation Reform Act ,Universal Registration Document ,Des March ,Annual Report ,Exchange Commission ,Englj Med ,Inventiva Stock Exchange ,News ,Information ,Press Release ,Fda ,Assessment ,Oncludes ,Hat ,The ,Hase ,Hi ,Combination ,Bay ,Fproceed ,Initiation ,F ,Trial ,Us ,Planned ,Or ,1 ,022 ,End ,Publication ,Topline ,Results ,Xpected ,2 ,023 Iva Fr0013233012 ,